An Open-label, Fixed-dose, Multicenter, Phase II Study of MDX-060 in Patients with Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma To determine the objective response rate at Day 50 in patients with relapsed or refractory classic systemic anaplastic large cell lymphoma (csALCL) or primary cutaneous anaplastic large cell lymphoma ...

• Country None
• organs None
• Specialty None

Medarex MDX010-20 : Essai de phase 3 randomisé, en double aveugle, comparant l’efficacité et la tolérance de 3 schémas thérapeutiques, MDX-010 seul ou associé à MDX-1379 et MDX1379 seul chez des patients ayant un mélanome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A randomized, double-blind, multicenter study comparing MDX-010 monotherapy, MDX-010 in combination with a melanoma peptide vaccine, and melanoma vaccine monotherapy in HLA-A2*0201-positive patients w...

• Country France
• organs Mélanomes cutanés
• Specialty Thérapies Ciblées, Immunothérapie - Vaccinothérapie

A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Vaccine, and Melanoma Peptide Vaccine Monotherapy in HLA-A*0201-Positive Patients with Previously Treated Unresectable Stage III or IV Melanoma To determine the safety and efficacy, measured as best objective response rate (BORR), of MDX-010 when administered in combination with a gp100 melanoma peptide vaccine and to demonstrate the independ...

• Country None
• organs None
• Specialty None